+353-1-416-8900REST OF WORLD
+44-20-3973-8888REST OF WORLD
1-917-300-0470EAST COAST U.S
1-800-526-8630U.S. (TOLL FREE)
New

Global Radiopharmaceutical Market (2023-2028) Competitive Analysis, Impact of Covid-19, Impact of Economic Slowdown & Impending Recession, Ansoff Analysis

  • PDF Icon

    Report

  • 167 Pages
  • February 2024
  • Region: Global
  • Infogence Global Research
  • ID: 5451234

New radiopharmaceuticals, technologies, products, and software are driving adoption in an increasingly uncertain healthcare environment

The Global Radiopharmaceutical Market is estimated to be USD 7.38 Bn in 2023 and is expected to reach USD 11.99 Bn by 2028 growing at a CAGR of 10.18%.

Market Dynamics

Market dynamics are forces that impact the prices and behaviors of the stakeholders. These forces create pricing signals which result from the changes in the supply and demand curves for a given product or service. Forces of Market Dynamics may be related to macro-economic and micro-economic factors. There are dynamic market forces other than price, demand, and supply. Human emotions can also drive decisions, influence the market, and create price signals.

As the market dynamics impact the supply and demand curves, decision-makers aim to determine the best way to use various financial tools to stem various strategies for speeding the growth and reducing the risks.

Market Segmentations

  • The Global Radiopharmaceutical Market is segmented based on Type, Applications, End-Users, and Geography.
  • By Type, the market is classified into Diagnostic Nuclear Medicine and Therapeutic Nuclear Medicine.
  • By Applications, the market is classified into Oncology, Cardiology, Gastroenterology, Neuroendocrinology, Neurology, and Nephrology.
  • By End-Users, the market is classified into Hospitals & Diagnostics Centres and Research Institutes.
  • By Geography, the market is classified into Americas, Europe, Middle-East & Africa, and Asia-Pacific.

Company Profiles

The report provides a detailed analysis of the competitors in the market. It covers the financial performance analysis for the publicly listed companies in the market. The report also offers detailed information on the companies' recent development and competitive scenario. Some of the companies covered in this report are GE HealthCare Technologies Inc., Jubilant Life Sciences Ltd., Lantheus Co., Lightpoint Medical Ltd., Mallinckrodt Pharmaceuticals, Nordion, Inc., etc.

Countries Studied

  • America (Argentina, Brazil, Canada, Chile, Colombia, Mexico, Peru, United States, Rest of Americas)
  • Europe (Austria, Belgium, Denmark, Finland, France, Germany, Italy, Netherlands, Norway, Poland, Russia, Spain, Sweden, Switzerland, United Kingdom, Rest of Europe)
  • Middle-East and Africa (Egypt, Israel, Qatar, Saudi Arabia, South Africa, United Arab Emirates, Rest of MEA)
  • Asia-Pacific (Australia, Bangladesh, China, India, Indonesia, Japan, Malaysia, Philippines, Singapore, South Korea, Sri Lanka, Thailand, Taiwan, Rest of Asia-Pacific)

Competitive Quadrant

The report includes Competitive Quadrant, a proprietary tool to analyze and evaluate the position of companies based on their Industry Position score and Market Performance score. The tool uses various factors for categorizing the players into four categories. Some of these factors considered for analysis are financial performance over the last 3 years, growth strategies, innovation score, new product launches, investments, growth in market share, etc.

Ansoff Analysis

  • The report presents a detailed Ansoff matrix analysis for the Global Radiopharmaceutical Market. Ansoff Matrix, also known as Product/Market Expansion Grid, is a strategic tool used to design strategies for the growth of the company. The matrix can be used to evaluate approaches in four strategies viz. Market Development, Market Penetration, Product Development, and Diversification. The matrix is also used for risk analysis to understand the risk involved with each approach.
  • The publisher analyses the Global Radiopharmaceutical Market using the Ansoff Matrix to provide the best approaches a company can take to improve its market position.
  • Based on the SWOT analysis conducted on the industry and industry players, the publisher has devised suitable strategies for market growth.

Why buy this report?

  • The report offers a comprehensive evaluation of the Global Radiopharmaceutical Market. The report includes in-depth qualitative analysis, verifiable data from authentic sources, and projections about market size. The projections are calculated using proven research methodologies.
  • The report has been compiled through extensive primary and secondary research. The primary research is done through interviews, surveys, and observation of renowned personnel in the industry.
  • The report includes an in-depth market analysis using Porter's 5 forces model, PESTLE Analysis, and the Ansoff Matrix. In addition, the impact of COVID-19 and the impact of economic slowdown & impending recession on the market are also featured in the report.
  • The report also includes the regulatory scenario in the industry, which will help you make a well-informed decision. The report discusses major regulatory bodies and major rules and regulations imposed on this sector across various geographies.
  • The report also contains the competitive analysis using Positioning Quadrants, the Proprietary competitive positioning tool.

Report Highlights:

  • A complete analysis of the market, including parent industry
  • Important market dynamics and trends
  • Market segmentation
  • Historical, current, and projected size of the market based on value and volume
  • Market shares and strategies of key players
  • Recommendations to companies for strengthening their foothold in the market

Table of Contents

1 Report Description
1.1 Study Objectives
1.2 Market Definition
1.3 Currency
1.4 Years Considered
1.5 Language
1.6 Key Stakeholders
2 Research Methodology
2.1 Research Process
2.2 Data Collection and Validation
2.2.1 Secondary Research
2.2.2 Primary Research
2.2.3 Models
2.3 Market Size Estimation
2.3.1 Bottom-Up Approach
2.3.2 Top-Down Approach
2.4 Assumptions of the Study
2.5 Limitations of the Study
3 Executive Summary
3.1 Introduction
3.2 Market Size, Segmentations, and Outlook
4 Market Dynamics
4.1 Drivers
4.1.1 High Demand for Early Diagnosis of Cancer and Cardiovascular Chronic Diseases
4.1.2 Rising Healthcare Expenditure
4.1.3 Alpha Radio-Immunotherapy-Based Targeted Cancer Treatment
4.2 Restraints
4.2.1 Stringent Regulatory Guidelines
4.2.2 High Cost of Devices Using Radioisotopes
4.3 Opportunities
4.3.1 Use of Radiopharmaceuticals in Neurological Applications
4.3.2 Growing Awareness about the Benefits of Radiopharmaceuticals amongst Healthcare Providers
4.3.3 Technological Advancements
4.4 Challenges
4.4.1 Short Half-Life of Radiopharmaceuticals
5 Market Analysis
5.1 Regulatory Scenario
5.2 Porter's Five Forces Analysis
5.3 PESTLE Analysis
5.4 Impact of COVID-19
5.5 Impact of Economic Slowdown & Impending Recession
5.6 Ansoff Matrix Analysis
6 Global Radiopharmaceutical Market, By Type
6.1 Introduction
6.2 Diagnostic Nuclear Medicine
6.2.1 Spect Radiopharmaceuticals
6.2.1.1 Technetium-Tc-99m)
6.2.1.2 Tl-201
6.2.1.3 Gallium-67
6.2.1.4 Iodine-(I-123)
6.2.2 PET Radiopharmaceuticals
6.2.2.1 Fludeoxyglucose (F-18)
6.2.2.2 Rubidium(Rb-82)
6.3 Therapeutic Nuclear Medicine
6.3.1 Alpha Emitters
6.3.2 Beta Emitters
6.3.3 Brachytherapy Isotopes
7 Global Radiopharmaceutical Market, By Applications
7.1 Introduction
7.2 Oncology
7.3 Cardiology
7.4 Gastroenterology
7.5 Neuroendocrinology
7.6 Neurology
7.7 Nephrology
7.8 Others
8 Global Radiopharmaceutical Market, By End-Users
8.1 Introduction
8.2 Hospitals & Diagnostics Centres
8.3 Research Institutes
9 Americas' Radiopharmaceutical Market
9.1 Introduction
9.2 Argentina
9.3 Brazil
9.4 Canada
9.5 Chile
9.6 Colombia
9.7 Mexico
9.8 Peru
9.9 United States
9.10 Rest of Americas
10 Europe's Radiopharmaceutical Market
10.1 Introduction
10.2 Austria
10.3 Belgium
10.4 Denmark
10.5 Finland
10.6 France
10.7 Germany
10.8 Italy
10.9 Netherlands
10.10 Norway
10.11 Poland
10.12 Russia
10.13 Spain
10.14 Sweden
10.15 Switzerland
10.16 United Kingdom
10.17 Rest of Europe
11 Middle East and Africa's Radiopharmaceutical Market
11.1 Introduction
11.2 Egypt
11.3 Israel
11.4 Qatar
11.5 Saudi Arabia
11.6 South Africa
11.7 United Arab Emirates
11.8 Rest of MEA
12 APAC's Radiopharmaceutical Market
12.1 Introduction
12.2 Australia
12.3 Bangladesh
12.4 China
12.5 India
12.6 Indonesia
12.7 Japan
12.8 Malaysia
12.9 Philippines
12.10 Singapore
12.11 South Korea
12.12 Sri Lanka
12.13 Thailand
12.14 Taiwan
12.15 Rest of Asia-Pacific
13 Competitive Landscape
13.1 Competitive Quadrant
13.2 Market Share Analysis
13.3 Strategic Initiatives
13.3.1 M&A and Investments
13.3.2 Partnerships and Collaborations
13.3.3 Product Developments and Improvements
14 Company Profiles
14.1 Advanced Accelerator Applications S.A
14.2 Aktis Oncology, Inc.
14.3 Alpha-9 Theranostics, Inc.
14.4 Bayer Ag
14.5 Bracco Imaging S.p.A
14.6 Cardinal Health, Inc.
14.7 Curium
14.8 Eckert & Ziegler Group
14.9 Eczacibasi-Monrol
14.10 Fusion Pharma
14.11 GE HealthCare Technologies Inc.
14.12 Jubilant Life Sciences Ltd.
14.13 Lantheus Co.
14.14 Lightpoint Medical Ltd.
14.15 Mallinckrodt Pharmaceuticals
14.16 Nordion, Inc.
14.17 NTP Radioisotopes SOC Ltd.
14.18 Precirix NV
14.19 RayzeBio, Inc.
14.20 The Institute of Radioelements
14.21 Viewpoint Molecular Targeting Inc.
15 Appendix
15.1 Questionnaire

Companies Mentioned

  • Advanced Accelerator Applications S.A
  • Aktis Oncology, Inc.
  • Alpha-9 Theranostics, Inc.
  • Bayer Ag
  • Bracco Imaging S.p.A
  • Cardinal Health, Inc.
  • Curium
  • Eckert & Ziegler Group
  • Eczacibasi-Monrol
  • Fusion Pharma
  • GE HealthCare Technologies Inc.
  • Jubilant Life Sciences Ltd.
  • Lantheus Co.
  • Lightpoint Medical Ltd.
  • Mallinckrodt Pharmaceuticals
  • Nordion, Inc.
  • NTP Radioisotopes SOC Ltd.
  • Precirix NV
  • RayzeBio, Inc.
  • The Institute of Radioelements
  • Viewpoint Molecular Targeting Inc.

Table Information